Anacor Pharma Reports Presentations of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at Two Upcoming Conferences

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that data from the Phase 3 pivotal studies of investigational drug Crisaborole Topical Ointment, 2% will be presented at two upcoming medical meetings. The Fall Clinical Dermatology Conference, October 1-4, 2015 in Las Vegas, Nevada The following abstracts have recently been accepted for poster presentation: "Results from Two Phase 3 Studies in Children and Adults with Mild to Moderate Atopic Dermatitis Treated with Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor" "Evaluation of Pruritus and Signs of Atopic Dermatitis With Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor in Two Phase 3 Studies in Children and Adults With Mild to Moderate Atopic Dermatitis" The 24th European Academy of Dermatology and Venereology Congress, October 7-11, 2015 in Copenhagen, Denmark LATCOP-0093, "Treatment of children and adults with mild to moderate atopic dermatitis with Crisaborole Topical Ointment, 2%, a novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies" will be presented during the late breaking news session on Saturday, October 10, between 8:00 a.m. and 11:15 a.m. CEST by Mark Lebwohl, M.D., Sol and Clara Kest Professor and Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai.